TARS Q1 2024 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$28M+1004.6% YoY

Gross Profit

$26M94.0% margin

Operating Income

-$38M-136.5% margin

Net Income

-$36M-129.4% margin

EPS (Diluted)

$-1.01

QoQ Revenue Growth

+111.2%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$38M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$349M

Total Liabilities

$74M

Stockholders' Equity

$275M

Cash & Equivalents

$194M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$28M	$3M	+1004.6%
Gross Profit	$26M	$2M	+1056.3%
Operating Income	-$38M	-$25M	-51.0%
Net Income	-$36M	-$23M	-52.6%

Revenue Segments

Product

$25M90%

License And Collaboration

$3M10%